Paradigm Shift to Promote a Revolution of Treatment of Schizophrenia to Achieve Recovery
Main Article Content
Abstract
Active schizophrenia is characterized by psychotic symptoms that can include delusions, hallucinations, disorganized speech, trouble with thinking, and a lack of motivation. The introduction of antipsychotics in the 50ties was called a revolution for the treatment of schizophrenia and psychosis and is now a cornerstone of treatment. The effects are considered well documented. Guidelines suggest that all patients be offered antipsychotics. Nearly all patients are medicated. Concerns have been raised about non-responders, and there is no evidence for long-term effects. The validity of the diagnosis of schizophrenia according to the Diagnostic and Statistical Manual Mental Disorders (DSM) is controversial and discussed. Patients experience side effects and low benefits and try to stop. This is considered non-conformance, which can lead to relapse. Therefore, caregivers consider medication necessary and use forced drugging. Antipsychotics reduce psychotic symptoms. New patient laws in many countries aim to promote recovery.
The United Nations Special Rapporteur on the Right to Health has called 2019 for «World needs a "revolution" in mental health care». "There is now unequivocal evidence of the failures of a system that relies too heavily on the biomedical model of mental health services, including the front-line and excessive use of psychotropic medicines, and yet these models persist". However, this proposal is highly controversial for clinicians.
World Health Organization (WHO) followed up 2021: “New WHO guidance seeks to put an end to human rights violations in mental health care”. "This comprehensive new guidance provides a strong argument for a much faster transition from mental health services that use coercion and focus almost exclusively on the use of medication to manage symptoms of mental health conditions to a more holistic approach that takes into account the specific circumstances and wishes of the individual and offers a variety of approaches for treatment and support".
This is highly controversial; however, the United Nations High Commissioner for Human Rights (OHCHR) supported the WHO proposal with a guideline to reform legislation in order to end human rights abuses and increase access to quality mental health care. A realistic path to implement WHO treatment improvements seems to need the courage of legislators to follow OHCHR suggestions and a shift of paradigm.
Article Details
How to Cite
KEIM, Walter.
Paradigm Shift to Promote a Revolution of Treatment of Schizophrenia to Achieve Recovery.
Medical Research Archives, [S.l.], v. 11, n. 12, dec. 2023.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/4866>. Date accessed: 21 nov. 2024.
doi: https://doi.org/10.18103/mra.v11i12.4866.
Section
Research Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. O Odegard. pattern of discharge from norwegian psychiatric hospitals before and after the introduction of the psychotropic drugs. Am J Psychiatry. 1964 Feb:120:772-8. doi: 10.1176/ajp.120.8.772.
2. Bockoven, J. S., & Solomon, H. C. (1975). Comparison of two five-year follow-up studies: 1947 to 1952 and 1967 to 1972. The American Journal of Psychiatry, 132(8), 796–801. https://doi.org/10.1176/ajp.132.8.796
3. N R Schooler, S C Goldberg, H Boothe, J O Cole. One year after discharge: community adjustment of schizophrenic patients. Am J Psychiatry. 1967 Feb;123(8):986-95. doi: 10.1176/ajp.123.8.986.
4. M Rappaport, H K Hopkins, K Hall, T Belleza, J Silverman. Are there schizophrenics for whom drugs may be unnecessary or contraindicated? Int Pharmacopsychiatry. 1978;13(2):100-11. doi: 10.1159/000468327.
5. Whitaker R: The Case Against Antipsychotics: A Review of Their Long-Term Side Effects. Cambridge,Mass, Mad in America Foundation, 2016 https://www.madinamerica.com/2016/07/the-case-against-antipsychotics/
6. Leucht, S., Arbter, D., Engel, R. et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14, 429–447 (2009). https://doi.org/10.1038/sj.mp.4002136
7. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012 May 16;(5):CD008016. doi: 10.1002/14651858.CD008016.pub2
8. Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bächer S, Cipriani A, Geddes JR, Salanti G, Davis JM. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. Am J Psychiatry. 2017 Oct 1;174(10):927-942. doi: 10.1176/appi.ajp.2017.16121358. Epub 2017 May 25. PMID: 28541090.
9. Robert Whitaker. The case against antipsychotic drugs: a 50-year record of doing more harm than good. Medical Hypotheses Volume 62, Issue 1, January 2004, Pages 5-13. https://doi.org/10.1016/S0306-9877(03)00293-7
10. Whitaker R: The Case Against Antipsychotics: A Review of Their Long-Term Side Effects. Cambridge, Mass, Mad in America Foundation, 2016 https://www.madinamerica.com/2016/07/the-case-against-antipsychotics/
11. Sohler N, Adams BG, Barnes DM, Cohen GH, Prins SJ, Schwartz S. Weighing the evidence for harm from long-term treatment with antipsychotic medications: A systematic review. Am J Orthopsychiatry. 2016;86(5):477-485. doi:10.1037/ort0000106
12. Robert Whitaker. The Case Against Antipsychotics. online publication July 25, 2016. https://www.madinamerica.com/2016/07/the-case-against-antipsychotics/
13. Dalsbø TK, Dahm, KT, Øvernes, LA, Lauritzen M, Skjelbakken T. [Effectiveness of treatment for psychosis: evidence base for a shared decision-making tool] Rapport 2019. Oslo: Folkehelseinstituttet, [Norwegian Institute of Public Health ] 2019.
14. Iversen TSJ, Steen NE, Dieset I, et al. Side effect burden of antipsychotic drugs in real life - Impact of gender and polypharmacy. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:263-271. doi:10.1016/j.pnpbp.2017.11.004 Nov 7. PMID: 29122637.
15. Lindström E, Lewander T, Malm U, Malt UF, Lublin H, Ahlfors UG. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry. 2001;55 Suppl 44:5-69. doi:10.1080/080394801317084428
16. Danborg PB, Gøtzsche PC. Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review. Int J Risk Saf Med. 2019;30(4):193-201. doi:10.3233/JRS-195063
17. Gøtzsche PC. Forced Drugging with Antipsychotics is Against the Law: Decision in Norway online publication Cambridge, Mass, Mad in America Foundation, 2016. https://www.madinamerica.com/2019/05/forced-drugging-antipsychotics-against-law/
18. Zinkler, M. Germany without Coercive Treatment in Psychiatry—A 15 Month Real World Experience. March 2016 Laws 5(1):15. DOI: 10.3390/laws5010015
19. Flammer E, Steinert T. [The Case Register for Coercive Measures According to the Law on Assistance for Persons with Mental Diseases of Baden-Wuerttemberg: Conception and First Evaluation]. Psychiatr Prax. 2019;46(2):82-89. doi:10.1055/a-0665-6728
20. Sanne Koops, Kelly Allott, Lieuwe de Haan, Eric Chen, Christy Hui, Eoin Killackey, Maria Long, Joanna Moncrieff, Iris Sommer, Anne Emilie Stürup, Lex Wunderink, Marieke Begemann, TAPER international research consortium, Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium, Schizophrenia Bulletin, 2023;, sbad112, https://doi.org/10.1093/schbul/sbad112
21. Begemann MJH, Thompson IA, Veling W, et al. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial. Trials. 2020;21(1):147. Published 2020 Feb 7. doi:10.1186/s13063-019-3822-5
22. Kudlow P. The perils of diagnostic inflation. CMAJ. 2013;185(1):E25-E26. doi:10.1503/cmaj.109-4371
23. Hyman SE. The Diagnosis of Mental Disorders: The Problem of Reification. Annual Review of Clinical Psychology. Vol. 6:155-179 (Volume publication date 27 April 2010). https://doi.org/10.1146/annurev.clinpsy.3.022806.091532
24. Insel, T. Post by Former NIMH Director Thomas Insel: Transforming Diagnosis. NMIH website 2013. https://web.archive.org/web/20210509074446/https://www.nimh.nih.gov/about/directors/thomas-insel/blog/2013/transforming-diagnosis
25. Aarre TF. A farewell to psychiatric diagnoses. Tidsskr Nor Legeforen 2022. doi: 10.4045/tidsskr.22.0386
26. Johannessen JO, Joa I. Modern understanding of psychosis: from brain disease to stress disorder. And some other important aspects of psychosis. Psychological, Social and Integrative Approaches Volume 13, 2021 - Issue 4 doi: 10.1080/17522439.2021.1985162
27. WHO. Mental health action plan 2013 – 2020 online publication 6 January 2013. https://www.who.int/publications/i/item/9789241506021
28. Funk M, Bold ND. WHO's QualityRights Initiative: Transforming Services and Promoting Rights in Mental Health. Health Hum Rights. 2020;22(1):69-75.
29. Robert W. Buchanan, Julie Kreyenbuhl, Deanna L. Kelly, Jason M. Noel, Douglas L. Boggs, Bernard A. Fischer, Seth Himelhoch, Beverly Fang, Eunice Peterson, Patrick R. Aquino, William Keller, The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements, Schizophrenia Bulletin, Volume 36, Issue 1, January 2010, Pages 71–93, https://doi.org/10.1093/schbul/sbp116
30. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012 May 16;(5):CD008016. doi: 10.1002/14651858.CD008016.pub2
31. Anna Ceraso, Jessie Jingxia Lin, Johannes Schneider-Thoma, Spyridon Siafis, Stephan Heres, Werner Kissling, John M Davis, Stefan Leucht, Maintenance Treatment With Antipsychotic Drugs in Schizophrenia: A Cochrane Systematic Review and Meta-analysis, Schizophrenia Bulletin, Volume 48, Issue 4, July 2022, Pages 738–740, https://doi.org/10.1093/schbul/sbac041
32. Jääskeläinen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6):1296-1306. doi:10.1093/schbul/sbs130
33. Harrow M, Jobe TH. Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study. J Nerv Ment Dis. 2007;195(5):406-414. doi:10.1097/01.nmd.0000253783.32338.6e
34. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy: Long-term Follow-up of a 2-Year Randomized Clinical Trial. JAMA Psychiatry. 2013;70(9):913–920. doi:10.1001/jamapsychiatry.2013.19
35. Martin Harrow, Thomas H. Jobe, Robert N. Faull, Jie Yang. A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia. Psychiatry Research, Volume 256, 2017, Pages 267-274. ISSN 0165-1781. https://doi.org/10.1016/j.psychres.2017.06.069
36. Harrow M, Jobe TH. Long-term antipsychotic treatment of schizophrenia: does it help or hurt over a 20-year period? World Psychiatry Volume17, Issue2, June 2018. https://doi.org/10.1002/wps.20518
37. Stephen Z. Levine, Jonathan Rabinowitz, Douglas Faries, Anthony H. Lawson, Haya Ascher-Svanum. Treatment response trajectories and antipsychotic medications: Examination of up to 18months of treatment in the CATIE chronic schizophrenia trial. Schizophrenia Research, Volume 137, Issues 1–3, 2012, Pages 141-146, ISSN 0920-9964, https://doi.org/10.1016/j.schres.2012.01.014
38. Tomi Bergström, Jaakko Seikkula, Birgitta Alakare, Pirjo Mäki, Päivi Köngäs-Saviaro, Jyri J. Taskila, Asko Tolvanen, Jukka Aaltonen. The family-oriented open dialogue approach in the treatment of first-episode psychosis: Nineteen–year outcomes. Psychiatry Research, Volume 270, 2018, Pages 168-175, ISSN 0165-1781. https://doi.org/10.1016/j.psychres.2018.09.039
39. University College London. Research into Antipsychotic Discontinuation and Reduction. This study is funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research (Grant Reference Number RP-PG-0514-20004)
40. Begemann MJH, Thompson IA, Veling W, et al. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial. Trials. 2020;21(1):147. Published 2020 Feb 7. doi:10.1186/s13063-019-3822-5
41. Myrto T Samara, Adriani Nikolakopoulou, Georgia Salanti, and Stefan Leucht. How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials. Schizophr Bull. 2019 Apr; 45(3): 639–646. Published online 2018 Jul 2. doi: 10.1093/schbul/sby095
42. John Read, Ann Sacia. Using Open Questions to Understand 650 People's Experiences With Antipsychotic Drugs. Schizophr Bull. 2020 Jul 8;46(4):896-904. doi: 10.1093/schbul/sbaa002
43. Read J, Williams J. Positive and Negative Effects of Antipsychotic Medication: An International Online Survey of 832 Recipients. Curr Drug Saf. 2019;14(3):173-181. doi:10.2174/1574886314666190301152734
44. Lindström E, Lewander T, Malm U, Malt UF, Lublin H, Ahlfors UG. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry. 2001;55 Suppl 44:5-69. doi:10.1080/080394801317084428
45. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication non-adherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909.
doi:10.4088/jcp.v63n1007
46. Dulcinea Vega, Francisco J. Acosta, Pedro Saavedra. Non-adherence after hospital discharge in patients with schizophrenia or schizoaffective disorder: A six-month naturalistic follow-up study. Comprehensive Psychiatry, Volume 108, 2021, 152240, ISSN 0010-440X. https://doi.org/10.1016/j.comppsych.2021.152240
47. Jeffrey A. Lieberman, M.D., and T. Scott Stroup. The NIMH-CATIE Schizophrenia Study: What Did We Learn? The American Journal of Psychiatry. Published Online:1 Aug 2011. https://doi.org/10.1176/appi.ajp.2011.11010039
48. Sanne Koops, Kelly Allott, Lieuwe de Haan, Eric Chen, Christy Hui, Eoin Killackey, Maria Long, Joanna Moncrieff, Iris Sommer, Anne Emilie Stürup, Lex Wunderink, Marieke Begemann, TAPER international research consortium, Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium, Schizophrenia Bulletin, 2023;, sbad112, https://doi.org/10.1093/schbul/sbad112
49. Standal K, Solbakken OA, Rugkåsa J, Martinsen AR, Halvorsen MS, Abbass A, Heiervang KS. Why Service Users Choose Medication-Free Psychiatric Treatment: A Mixed-Method Study of User Accounts. Patient Prefer Adherence. 2021;15:1647-1660. https://doi.org/10.2147/PPA.S308151
50. McHugh RK, Whitton SW, Peckham AD, Welge JA, Otto MW. Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. J Clin Psychiatry. 2013;74(6):595-602. doi:10.4088/JCP.12r07757
51. Sebastian von Peter, Martin Zinkler. Coping with Criticism and Embracing Change—Further Reflexions on the Debate on a Mental Health Care System without Coercion. Laws 2021, 10(2), 22; https://doi.org/10.3390/laws10020022
52. Jeppe Oute, Susan McPherson. Conflict and antagonism within global psychiatry: A discourse analysis of organisational responses to the UN reports on rights-based approaches in mental health. Sociology of Health & Illness, First published: 05 October 2023. https://doi.org/10.1111/1467-9566.13717
53. World Psychiatric Association. Supporting and implementing alternatives to coercion in mental health care. https://www.wpanet.org/alternatives-to-coercion
54. Committee on the Rights of Persons with Disabilities. Eleventh session. 31 March–11 April 2014.General comment No. 1 (2014). https://tbinternet.ohchr.org/_layouts/15/treatybodyexternal/Download.aspx?symbolno=CRPD/C/GC/1&Lang=en
55. Bola J, Kao D, Soydan H. Antipsychotic medication for early episode schizophrenia. Cochrane Database Syst Rev. 2011;2011(6):CD006374. Published 2011 Jun 15. doi:10.1002/14651858.CD006374.pub2
56. The United Nations Special Rapporteur on the right to health, Dainius Puras “World needs “revolution” in mental health care – UN rights expert” online publication 06 June 2017. https://www.ohchr.org/en/press-releases/2017/06/world-needs-revolution-mental-health-care-un-rights-expert?LangID=E
57. WHO “New WHO guidance seeks to put an end to human rights violations in mental health care” online publication 10 June 2021. https://www.who.int/news/item/10-06-2021-new-who-guidance-seeks-to-put-an-end-to-human-rights-violations-in-mental-health-care
58. F.E. Morrissey. An evaluation of attitudinal change towards CRPD rights following delivery of the WHO QualityRights training programme. Ethics, Medicine and Public Health, Volume 13, 2020, 100410, ISSN 2352-5525. https://doi.org/10.1016/j.jemep.2019.100410
59. WHO-OHCHR launch new guidance to improve laws addressing human rights abuses in mental health care. 9 October 2023. https://www.who.int/news/item/09-10-2023-who-ohchr-launch-new-guidance-to-improve-laws-addressing-human-rights-abuses-in-mental-health-care
2. Bockoven, J. S., & Solomon, H. C. (1975). Comparison of two five-year follow-up studies: 1947 to 1952 and 1967 to 1972. The American Journal of Psychiatry, 132(8), 796–801. https://doi.org/10.1176/ajp.132.8.796
3. N R Schooler, S C Goldberg, H Boothe, J O Cole. One year after discharge: community adjustment of schizophrenic patients. Am J Psychiatry. 1967 Feb;123(8):986-95. doi: 10.1176/ajp.123.8.986.
4. M Rappaport, H K Hopkins, K Hall, T Belleza, J Silverman. Are there schizophrenics for whom drugs may be unnecessary or contraindicated? Int Pharmacopsychiatry. 1978;13(2):100-11. doi: 10.1159/000468327.
5. Whitaker R: The Case Against Antipsychotics: A Review of Their Long-Term Side Effects. Cambridge,Mass, Mad in America Foundation, 2016 https://www.madinamerica.com/2016/07/the-case-against-antipsychotics/
6. Leucht, S., Arbter, D., Engel, R. et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14, 429–447 (2009). https://doi.org/10.1038/sj.mp.4002136
7. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012 May 16;(5):CD008016. doi: 10.1002/14651858.CD008016.pub2
8. Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bächer S, Cipriani A, Geddes JR, Salanti G, Davis JM. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. Am J Psychiatry. 2017 Oct 1;174(10):927-942. doi: 10.1176/appi.ajp.2017.16121358. Epub 2017 May 25. PMID: 28541090.
9. Robert Whitaker. The case against antipsychotic drugs: a 50-year record of doing more harm than good. Medical Hypotheses Volume 62, Issue 1, January 2004, Pages 5-13. https://doi.org/10.1016/S0306-9877(03)00293-7
10. Whitaker R: The Case Against Antipsychotics: A Review of Their Long-Term Side Effects. Cambridge, Mass, Mad in America Foundation, 2016 https://www.madinamerica.com/2016/07/the-case-against-antipsychotics/
11. Sohler N, Adams BG, Barnes DM, Cohen GH, Prins SJ, Schwartz S. Weighing the evidence for harm from long-term treatment with antipsychotic medications: A systematic review. Am J Orthopsychiatry. 2016;86(5):477-485. doi:10.1037/ort0000106
12. Robert Whitaker. The Case Against Antipsychotics. online publication July 25, 2016. https://www.madinamerica.com/2016/07/the-case-against-antipsychotics/
13. Dalsbø TK, Dahm, KT, Øvernes, LA, Lauritzen M, Skjelbakken T. [Effectiveness of treatment for psychosis: evidence base for a shared decision-making tool] Rapport 2019. Oslo: Folkehelseinstituttet, [Norwegian Institute of Public Health ] 2019.
14. Iversen TSJ, Steen NE, Dieset I, et al. Side effect burden of antipsychotic drugs in real life - Impact of gender and polypharmacy. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:263-271. doi:10.1016/j.pnpbp.2017.11.004 Nov 7. PMID: 29122637.
15. Lindström E, Lewander T, Malm U, Malt UF, Lublin H, Ahlfors UG. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry. 2001;55 Suppl 44:5-69. doi:10.1080/080394801317084428
16. Danborg PB, Gøtzsche PC. Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review. Int J Risk Saf Med. 2019;30(4):193-201. doi:10.3233/JRS-195063
17. Gøtzsche PC. Forced Drugging with Antipsychotics is Against the Law: Decision in Norway online publication Cambridge, Mass, Mad in America Foundation, 2016. https://www.madinamerica.com/2019/05/forced-drugging-antipsychotics-against-law/
18. Zinkler, M. Germany without Coercive Treatment in Psychiatry—A 15 Month Real World Experience. March 2016 Laws 5(1):15. DOI: 10.3390/laws5010015
19. Flammer E, Steinert T. [The Case Register for Coercive Measures According to the Law on Assistance for Persons with Mental Diseases of Baden-Wuerttemberg: Conception and First Evaluation]. Psychiatr Prax. 2019;46(2):82-89. doi:10.1055/a-0665-6728
20. Sanne Koops, Kelly Allott, Lieuwe de Haan, Eric Chen, Christy Hui, Eoin Killackey, Maria Long, Joanna Moncrieff, Iris Sommer, Anne Emilie Stürup, Lex Wunderink, Marieke Begemann, TAPER international research consortium, Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium, Schizophrenia Bulletin, 2023;, sbad112, https://doi.org/10.1093/schbul/sbad112
21. Begemann MJH, Thompson IA, Veling W, et al. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial. Trials. 2020;21(1):147. Published 2020 Feb 7. doi:10.1186/s13063-019-3822-5
22. Kudlow P. The perils of diagnostic inflation. CMAJ. 2013;185(1):E25-E26. doi:10.1503/cmaj.109-4371
23. Hyman SE. The Diagnosis of Mental Disorders: The Problem of Reification. Annual Review of Clinical Psychology. Vol. 6:155-179 (Volume publication date 27 April 2010). https://doi.org/10.1146/annurev.clinpsy.3.022806.091532
24. Insel, T. Post by Former NIMH Director Thomas Insel: Transforming Diagnosis. NMIH website 2013. https://web.archive.org/web/20210509074446/https://www.nimh.nih.gov/about/directors/thomas-insel/blog/2013/transforming-diagnosis
25. Aarre TF. A farewell to psychiatric diagnoses. Tidsskr Nor Legeforen 2022. doi: 10.4045/tidsskr.22.0386
26. Johannessen JO, Joa I. Modern understanding of psychosis: from brain disease to stress disorder. And some other important aspects of psychosis. Psychological, Social and Integrative Approaches Volume 13, 2021 - Issue 4 doi: 10.1080/17522439.2021.1985162
27. WHO. Mental health action plan 2013 – 2020 online publication 6 January 2013. https://www.who.int/publications/i/item/9789241506021
28. Funk M, Bold ND. WHO's QualityRights Initiative: Transforming Services and Promoting Rights in Mental Health. Health Hum Rights. 2020;22(1):69-75.
29. Robert W. Buchanan, Julie Kreyenbuhl, Deanna L. Kelly, Jason M. Noel, Douglas L. Boggs, Bernard A. Fischer, Seth Himelhoch, Beverly Fang, Eunice Peterson, Patrick R. Aquino, William Keller, The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements, Schizophrenia Bulletin, Volume 36, Issue 1, January 2010, Pages 71–93, https://doi.org/10.1093/schbul/sbp116
30. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012 May 16;(5):CD008016. doi: 10.1002/14651858.CD008016.pub2
31. Anna Ceraso, Jessie Jingxia Lin, Johannes Schneider-Thoma, Spyridon Siafis, Stephan Heres, Werner Kissling, John M Davis, Stefan Leucht, Maintenance Treatment With Antipsychotic Drugs in Schizophrenia: A Cochrane Systematic Review and Meta-analysis, Schizophrenia Bulletin, Volume 48, Issue 4, July 2022, Pages 738–740, https://doi.org/10.1093/schbul/sbac041
32. Jääskeläinen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6):1296-1306. doi:10.1093/schbul/sbs130
33. Harrow M, Jobe TH. Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study. J Nerv Ment Dis. 2007;195(5):406-414. doi:10.1097/01.nmd.0000253783.32338.6e
34. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy: Long-term Follow-up of a 2-Year Randomized Clinical Trial. JAMA Psychiatry. 2013;70(9):913–920. doi:10.1001/jamapsychiatry.2013.19
35. Martin Harrow, Thomas H. Jobe, Robert N. Faull, Jie Yang. A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia. Psychiatry Research, Volume 256, 2017, Pages 267-274. ISSN 0165-1781. https://doi.org/10.1016/j.psychres.2017.06.069
36. Harrow M, Jobe TH. Long-term antipsychotic treatment of schizophrenia: does it help or hurt over a 20-year period? World Psychiatry Volume17, Issue2, June 2018. https://doi.org/10.1002/wps.20518
37. Stephen Z. Levine, Jonathan Rabinowitz, Douglas Faries, Anthony H. Lawson, Haya Ascher-Svanum. Treatment response trajectories and antipsychotic medications: Examination of up to 18months of treatment in the CATIE chronic schizophrenia trial. Schizophrenia Research, Volume 137, Issues 1–3, 2012, Pages 141-146, ISSN 0920-9964, https://doi.org/10.1016/j.schres.2012.01.014
38. Tomi Bergström, Jaakko Seikkula, Birgitta Alakare, Pirjo Mäki, Päivi Köngäs-Saviaro, Jyri J. Taskila, Asko Tolvanen, Jukka Aaltonen. The family-oriented open dialogue approach in the treatment of first-episode psychosis: Nineteen–year outcomes. Psychiatry Research, Volume 270, 2018, Pages 168-175, ISSN 0165-1781. https://doi.org/10.1016/j.psychres.2018.09.039
39. University College London. Research into Antipsychotic Discontinuation and Reduction. This study is funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research (Grant Reference Number RP-PG-0514-20004)
40. Begemann MJH, Thompson IA, Veling W, et al. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial. Trials. 2020;21(1):147. Published 2020 Feb 7. doi:10.1186/s13063-019-3822-5
41. Myrto T Samara, Adriani Nikolakopoulou, Georgia Salanti, and Stefan Leucht. How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials. Schizophr Bull. 2019 Apr; 45(3): 639–646. Published online 2018 Jul 2. doi: 10.1093/schbul/sby095
42. John Read, Ann Sacia. Using Open Questions to Understand 650 People's Experiences With Antipsychotic Drugs. Schizophr Bull. 2020 Jul 8;46(4):896-904. doi: 10.1093/schbul/sbaa002
43. Read J, Williams J. Positive and Negative Effects of Antipsychotic Medication: An International Online Survey of 832 Recipients. Curr Drug Saf. 2019;14(3):173-181. doi:10.2174/1574886314666190301152734
44. Lindström E, Lewander T, Malm U, Malt UF, Lublin H, Ahlfors UG. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry. 2001;55 Suppl 44:5-69. doi:10.1080/080394801317084428
45. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication non-adherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909.
doi:10.4088/jcp.v63n1007
46. Dulcinea Vega, Francisco J. Acosta, Pedro Saavedra. Non-adherence after hospital discharge in patients with schizophrenia or schizoaffective disorder: A six-month naturalistic follow-up study. Comprehensive Psychiatry, Volume 108, 2021, 152240, ISSN 0010-440X. https://doi.org/10.1016/j.comppsych.2021.152240
47. Jeffrey A. Lieberman, M.D., and T. Scott Stroup. The NIMH-CATIE Schizophrenia Study: What Did We Learn? The American Journal of Psychiatry. Published Online:1 Aug 2011. https://doi.org/10.1176/appi.ajp.2011.11010039
48. Sanne Koops, Kelly Allott, Lieuwe de Haan, Eric Chen, Christy Hui, Eoin Killackey, Maria Long, Joanna Moncrieff, Iris Sommer, Anne Emilie Stürup, Lex Wunderink, Marieke Begemann, TAPER international research consortium, Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium, Schizophrenia Bulletin, 2023;, sbad112, https://doi.org/10.1093/schbul/sbad112
49. Standal K, Solbakken OA, Rugkåsa J, Martinsen AR, Halvorsen MS, Abbass A, Heiervang KS. Why Service Users Choose Medication-Free Psychiatric Treatment: A Mixed-Method Study of User Accounts. Patient Prefer Adherence. 2021;15:1647-1660. https://doi.org/10.2147/PPA.S308151
50. McHugh RK, Whitton SW, Peckham AD, Welge JA, Otto MW. Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. J Clin Psychiatry. 2013;74(6):595-602. doi:10.4088/JCP.12r07757
51. Sebastian von Peter, Martin Zinkler. Coping with Criticism and Embracing Change—Further Reflexions on the Debate on a Mental Health Care System without Coercion. Laws 2021, 10(2), 22; https://doi.org/10.3390/laws10020022
52. Jeppe Oute, Susan McPherson. Conflict and antagonism within global psychiatry: A discourse analysis of organisational responses to the UN reports on rights-based approaches in mental health. Sociology of Health & Illness, First published: 05 October 2023. https://doi.org/10.1111/1467-9566.13717
53. World Psychiatric Association. Supporting and implementing alternatives to coercion in mental health care. https://www.wpanet.org/alternatives-to-coercion
54. Committee on the Rights of Persons with Disabilities. Eleventh session. 31 March–11 April 2014.General comment No. 1 (2014). https://tbinternet.ohchr.org/_layouts/15/treatybodyexternal/Download.aspx?symbolno=CRPD/C/GC/1&Lang=en
55. Bola J, Kao D, Soydan H. Antipsychotic medication for early episode schizophrenia. Cochrane Database Syst Rev. 2011;2011(6):CD006374. Published 2011 Jun 15. doi:10.1002/14651858.CD006374.pub2
56. The United Nations Special Rapporteur on the right to health, Dainius Puras “World needs “revolution” in mental health care – UN rights expert” online publication 06 June 2017. https://www.ohchr.org/en/press-releases/2017/06/world-needs-revolution-mental-health-care-un-rights-expert?LangID=E
57. WHO “New WHO guidance seeks to put an end to human rights violations in mental health care” online publication 10 June 2021. https://www.who.int/news/item/10-06-2021-new-who-guidance-seeks-to-put-an-end-to-human-rights-violations-in-mental-health-care
58. F.E. Morrissey. An evaluation of attitudinal change towards CRPD rights following delivery of the WHO QualityRights training programme. Ethics, Medicine and Public Health, Volume 13, 2020, 100410, ISSN 2352-5525. https://doi.org/10.1016/j.jemep.2019.100410
59. WHO-OHCHR launch new guidance to improve laws addressing human rights abuses in mental health care. 9 October 2023. https://www.who.int/news/item/09-10-2023-who-ohchr-launch-new-guidance-to-improve-laws-addressing-human-rights-abuses-in-mental-health-care